Moreover, exploring novel costimulatory domains such as OX40 (CD134) or incorporating dual costimulatory signals may further optimize T-cell function and persistence, offering promising avenues for enhancing CAR-T cell therapy in CRC.119,120. This evidence concerns the gene TNFRSF4 and colorectal carcinoma.